News & Insights

  • Clear

AG James Secures Another Agreement to Cap Insulin Prices for Uninsured New Yorkers

New York AG Letitia James entered an agreement with Novo Nordisk Inc. to resolve an investigation into insulin marketing and pricing practices. Under the terms of the agreement, Novo Nordisk will cap the price of their insulin products at $35 per monthly prescription for uninsured New Yorkers for a period of five years. The company…

Read More

Clear Skies on the Horizon for Amgen’s Planned Acquisition

Amgen Inc. is settling challenges by six Democratic AGs and the FTC to its proposed acquisition of Horizon Therapeutics plc. As we previously reported, the AGs and the FTC alleged that the acquisition was anticompetitive, as it would allow Amgen to leverage its large market share to foreclose competition against certain Horizon Therapeutic treatments for…

Read More

Texas OAG Reaches $42.7 Million Settlement over Alleged Medicaid Fraud

The Texas OAG settled with six subsidiaries of Takeda Pharmaceutical Co. to resolve allegations that the companies committed Medicaid fraud in violation of the Texas Medicaid Fraud Prevention Act (TMFPA). According to the AG’s office, the settlement addresses alleged TMFPA violations raised by a whistleblower in a qui tam lawsuit. The lawsuit alleged that the…

Read More

Surescripts Settlement Shores Up Competition in E-Prescription Market

The FTC settled with Surescripts, LLC to resolve allegations that the health information technology company violated the FTC Act by engaging in anticompetitive, monopolistic conduct. The FTC’s complaint alleged that Surescripts utilized anticompetitive tactics to maintain monopolies in two markets related to electronic prescriptions: routing, or transmission between a provider and a pharmacy; and eligibility,…

Read More

340B Drug Discount Program Garners AG Concern and Recommendations

A bipartisan coalition of 23 AGs (21 Democrats and 2 Republicans) sent a letter in response to a request for information issued by a bipartisan group of U.S. Senators to strengthen the 340B Drug Pricing Program, which requires drug manufacturers participating in Medicaid and Medicare to provide discounted drugs to covered entities that serve financially…

Read More